Evidence map›Paper›PMID 35137372›Full record

ArticleAdvances in experimental medicine and biology2021

Current Challenges for the Effective Management of the COVID-19 Pandemic.

Vibha Sinha, Saurabh Saxena, Sanjay Kumar Pandey, Sudhakar Dwivedi, Suresh Thakur, Alexzander Asea, Ashwini Kumar Dixit, Vineeta Dixit, Naveen Kumar Vishvakarma, Dhananjay Shukla

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Vibha SinhaDepartment of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, India.
Saurabh SaxenaDepartment of Medical Laboratory Sciences, Lovely Professional University, Phagwara, Punjab, India.
Sanjay Kumar PandeyMultidisciplinary Research Unit, Shyam Shah Medical College, Rewa, Madhya Pradesh, India.
Sudhakar DwivediMultidisciplinary Research Unit, Shyam Shah Medical College, Rewa, Madhya Pradesh, India.
Suresh ThakurNextGen In-vitro Diagnostics Pvt Ltd., Gurugram, Haryana, India.
Alexzander AseaPresident & CEO, NampEVA BioTherapeutics LLC, Dover, DE, USA.
Ashwini Kumar DixitDepartment of Botany, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, India.
Vineeta DixitDepartment of Botany, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, India.
Naveen Kumar VishvakarmaDepartment of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, India.
Dhananjay ShuklaDepartment of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, India. sdhannu@gmail.com.
Guru Ghasidas Vishwavidyalaya · INShyam Shah Medical College · INLovely Professional University · INPrecision Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWithin a short period, the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) spread all over the globe and became the first pandemic of the present century. Early diagnostic tools and effective drugs are urgently needed to effectively manage the COVID-19 pandemic. Based on current literature, we provide recent updates on SARS-CoV-2 biology, available diagnostic methods, and therapeutic options for the management of COVID-19 pandemic.

methodsA literature survey was done using Google and PubMed and Web of Science to summarize the current updates on this topic.

resultsCurrent coronavirus diagnostic tests are reverse transcription polymerase chain reaction (RT-PCR), real-time RT-PCR (qRT-PCR), and reverse transcription loop-mediated isothermal amplification (RT-LAMP) which detects the presence of specific genome sequence of virus. Existing antiviral drugs or new therapeutic options such as neutralizing antibody or plasma therapy are mostly used to restrict the virus growth with a limited success.

conclusionAs there is no specific treatment or vaccine available to limit the infection of SARS-CoV-2, we need to rely on the existing way to limit the disease. The first priority to fight COVID-19 is development of early diagnostic tools so that infected persons can be identified and further viral transmission can be blocked. Evaluation of existing drugs or identification of new therapeutic entities becomes the major challenge to deal with the present pandemic.

Indexed as

COVID-19PandemicsHumansMolecular Diagnostic TechniquesReal-Time Polymerase Chain ReactionReverse TranscriptionRNA, ViralSARS-CoV-2Sensitivity and SpecificityRNA, ViralEpidemiologyNasopharyngealOropharyngealRT-LAMPRT-PCRSARS-CoV-2Vaccines

Identifiers

PMID35137372
OpenAlexW4210937229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.